Evidence map›Paper›PMID 31932455›Full record

ArticleCancer research2020

The Risk of Ovarian Cancer Increases with an Increase in the Lifetime Number of Ovulatory Cycles: An Analysis from the Ovarian Cancer Cohort Consortium (OC3).

Britton Trabert, Shelley S Tworoger, Katie M O'Brien, Mary K Townsend, Renée T Fortner, Edwin S Iversen, Patricia Hartge, Emily White, Pilar Amiano, Alan A Arslan and 41 more

Open access · bronzeAbstract read
In one paragraph

Article in Cancer research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
7.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 57 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. The Association of Kidney Function and Inflammatory Biomarkers with Epithelial Ovarian Cancer Risk.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023
    Article
  17. Article
  18. Article
  19. Molecular Management of High-Grade Serous Ovarian Carcinoma.International journal of molecular sciences · 2022
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors at 20 institutions in 12 countries.

Britton TrabertDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland. britton.trabert@nih.gov.ORCID 0000-0002-1539-6090
Shelley S TworogerDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0002-6986-7046
Katie M O'BrienEpidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, Durham, North Carolina.ORCID 0000-0002-1931-1349
Mary K TownsendDepartment of Cancer Epidemiology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.ORCID 0000-0003-2452-4477
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.ORCID 0000-0002-1426-8505
Edwin S IversenDepartment of Statistical Science, Duke University, Durham, North Carolina.
Patricia HartgeDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Emily WhiteDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Pilar AmianoPublic Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain.
Alan A ArslanNew York University School of Medicine, NYU Langone Health, New York, New York.
Leslie BernsteinCity of Hope, Duarte, California.ORCID 0000-0002-7692-6518
Louise A BrintonDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Julie E BuringDivision of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Laure DossusIARC, Lyon, France.
Gary E FraserLoma Linda University, Loma Linda, California.
Mia M GaudetBehavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia.ORCID 0000-0002-6429-4007
Graham G GilesCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID 0000-0003-4946-9099
Inger T GramDepartment of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Holly R HarrisDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.ORCID 0000-0002-2572-6727
Judith Hoffman BoltonJohns Hopkins Bloomberg School of Public Health and Johns Hopkins School of Medicine, Baltimore, Maryland.
Annika IdahlDepartment of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden.
Michael E JonesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-7479-3451
Rudolf KaaksDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Victoria A KirshDivision of Epidemiology, Dalla Lana School of Public Health, University of Toronto, Toronto, Canada.
Synnove F KnutsenLoma Linda University, Loma Linda, California.
Marina KvaskoffCESP, Fac. de médecine-Univ. Paris-Sud, Fac. de médecine-UVSQ, INSERM, Université Paris-Saclay, Villejuif, France.ORCID 0000-0002-4557-3772
James V LaceyCity of Hope, Duarte, California.
I-Min LeeDivision of Preventive Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Roger L MilneCancer Epidemiology Division, Cancer Council Victoria, Melbourne, Victoria, Australia.ORCID 0000-0001-5764-7268
N Charlotte Onland-MoretJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, University Utrecht, Utrecht, the Netherlands.ORCID 0000-0002-2360-913X
Kim OvervadDepartment of Public Health, Aarhus University, Aarhus, Denmark.
Alpa V PatelBehavioral and Epidemiology Research Group, American Cancer Society, Atlanta, Georgia.
Ulrike PetersDivision of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Jenny N PoynterDivision of Pediatric Epidemiology and Clinical Research, University of Minnesota, Minneapolis, Minnesota.ORCID 0000-0002-8460-3938
Elio RiboliSchool of Public Health, Imperial College London, United Kingdom.
Kim RobienDepartment of Exercise and Nutrition Sciences, Milken Institute School of Public Health, George Washington University, Washington, D.C.ORCID 0000-0002-2120-2280
Thomas E RohanDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York.
Dale P SandlerEpidemiology Branch, National Institute of Environmental Health Sciences, NIH, Research Triangle Park, Durham, North Carolina.ORCID 0000-0002-6776-0018
Catherine SchairerDivision of Cancer Epidemiology and Genetics, NCI, NIH, Bethesda, Maryland.
Leo J SchoutenGROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.ORCID 0000-0003-3361-7560
Veronica W SetiawanUniversity of Southern California, Los Angeles, California.
Anthony J SwerdlowDivision of Genetics and Epidemiology and Division of Breast Cancer Research, The Institute of Cancer Research, London, United Kingdom.ORCID 0000-0001-5550-4159
Ruth C TravisCancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom.
Antonia TrichopoulouHellenic Health Foundation, Athens, Greece.
Piet A van den BrandtGROW-School for Oncology and Developmental Biology, Maastricht University, Maastricht, the Netherlands.ORCID 0000-0001-8781-8099
Kala VisvanathanDepartment of Community Medicine, University of Tromsø, The Arctic University of Norway, Tromsø, Norway.
Lynne R WilkensPopulation Sciences in the Pacific Program (Cancer Epidemiology), University of Hawaii Cancer Center, Honolulu, Hawaii.
Alicja WolkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-7387-6845
Anne Zeleniuch-JacquotteNew York University School of Medicine, NYU Langone Health, New York, New York.
Nicolas Wentzensen
Ovarian Cancer Cohort Consortium (OC3)
Center for Cancer Research · USAmerican Cancer Society · USBrigham and Women's Hospital · USCity Of Hope National Medical Center · USFred Hutch Cancer Center · USGerman Cancer Research Center · DELoma Linda University · USMaastricht University · NLMoffitt Cancer Center · USNational Institute of Environmental Health Sciences · USNYU Langone Health · USUiT The Arctic University of Norway · NOAarhus University · DKAlbert Einstein College of Medicine · USBiogipuzkoa Health Research Institute · ESBreast Cancer Now · GBCancer Center of Hawaii · USCancer Council Victoria · AUCancer Research UK · GBHellenic Health Foundation · GR

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Statistical MethodsP01CA087969 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ROSNER, BERNARD A · 2000 to 2019
$77.8M
University of Hawaii Cancer Center CCSGP30CA071789 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI GERTRAUD MASKARINEC · 1996 to 2026
$56.2M
Understanding Population Differences in Cancer: The MEC StudyU01CA164973 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI HAIMAN, CHRISTOPHER ALAN, LE MARCHAND, LOIC · 2015 to 2025
$37.4M
PLCO Trial Etiologic and Early Marker StudyZIACP010152 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MOORE, STEVEN · 2009 to 2025
$29.9M
CALIFORNIA TEACHERS STUDYR01CA077398 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERNSTEIN, LESLIE · 1998 to 2014
$29.7M
Women's Health Study: Continued Follow-upR01CA047988 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E., LEE, I-MIN · 1991 to 2014
$28.2M
RESEARCH IN ENVIRONMENTAL HEALTH SCIENCES (CENTER GRANT)P30ES000260 · NIEHS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ZELIKOFF, JUDITH TERRY · 1985 to 2020
$26.1M
Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Therapeutic and Diagnostic Factors as Related to Cancer RiskZIACP010128 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$8.1M
EPIDEMIOLOGY OF CANCER IN A COHORT OF OLDER WOMENR01CA039742 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI LAZOVICH, DEANN · 1985 to 2014
$8.0M
Women's Health Study: Continued Follow-UpR01HL080467 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI BURING, JULIE E. · 2005 to 2010
$4.5M
Cancer Research UK 14136Cancer Research UK C570/A16491Cancer Research UK C8221/A19170Intramural NIH HHS Z01 CP010128Intramural NIH HHS Z01 ES044005Intramural NIH HHS ZIA CP010128Medical Research Council 1000143Medical Research Council G0401527Medical Research Council G1000143Medical Research Council MR/M012190/1Medical Research Council MR/N003284/1NCI NIH HHS K05 CA154337NCI NIH HHS K22 CA193860NCI NIH HHS P01 CA087969NCI NIH HHS P30 CA016087NCI NIH HHS P30 CA071789NCI NIH HHS R01 CA039742NCI NIH HHS R01 CA047988NCI NIH HHS R01 CA077398NCI NIH HHS U01 CA164973NCI NIH HHS U01 CA182913NCI NIH HHS UM1 CA182913NCI NIH HHS UM1 CA182934NCI NIH HHS UM1 CA186107NHLBI NIH HHS R01 HL043851NHLBI NIH HHS R01 HL080467NHLBI NIH HHS RC1 HL099355NIEHS NIH HHS P30 ES000260World Health Organization 001
6 · The paper itself

Abstract

Repeated exposure to the acute proinflammatory environment that follows ovulation at the ovarian surface and distal fallopian tube over a woman's reproductive years may increase ovarian cancer risk. To address this, analyses included individual-level data from 558,709 naturally menopausal women across 20 prospective cohorts, among whom 3,246 developed invasive epithelial ovarian cancer (2,045 serous, 319 endometrioid, 184 mucinous, 121 clear cell, 577 other/unknown). Cox models were used to estimate multivariable-adjusted HRs between lifetime ovulatory cycles (LOC) and its components and ovarian cancer risk overall and by histotype. Women in the 90th percentile of LOC (>514 cycles) were almost twice as likely to be diagnosed with ovarian cancer than women in the 10th percentile (<294) [HR (95% confidence interval): 1.92 (1.60-2.30)]. Risk increased 14% per 5-year increase in LOC (60 cycles) [(1.10-1.17)]; this association remained after adjustment for LOC components: number of pregnancies and oral contraceptive use [1.08 (1.04-1.12)]. The association varied by histotype, with increased risk of serous [1.13 (1.09-1.17)], endometrioid [1.20 (1.10-1.32)], and clear cell [1.37 (1.18-1.58)], but not mucinous [0.99 (0.88-1.10), P-heterogeneity = 0.01] tumors. Heterogeneity across histotypes was reduced [P-heterogeneity = 0.15] with adjustment for LOC components [1.08 serous, 1.11 endometrioid, 1.26 clear cell, 0.94 mucinous]. Although the 10-year absolute risk of ovarian cancer is small, it roughly doubles as the number of LOC rises from approximately 300 to 500. The consistency and linearity of effects strongly support the hypothesis that each ovulation leads to small increases in the risk of most ovarian cancers, a risk that cumulates through life, suggesting this as an important area for identifying intervention strategies. SIGNIFICANCE: Although ovarian cancer is rare, risk of most ovarian cancers doubles as the number of lifetime ovulatory cycles increases from approximately 300 to 500. Thus, identifying an important area for cancer prevention research.

Indexed as

AgedContraceptive AgentsFallopian TubesFemaleHumansMiddle AgedOvarian NeoplasmsOvaryOvulationProportional Hazards ModelsProspective StudiesReproductive HistoryRisk AssessmentRisk FactorsContraceptive Agents

Identifiers

PMID31932455
PMCPMC7056529
OpenAlexW3000562243

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.